MedDataX Logo

Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

NCT ID: NCT00396110

Last Updated: 2006-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3889 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C \< 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia Coronary Heart Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

cholesterol coronary heart disease rosuvastatin LDL-C goal hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* High-risk patients with and without evident CHD who had LDL-C \> 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
* Patients were aged \>18 years and \<70 years (men) and \< 75 years (women).

Exclusion Criteria

* Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
* Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ingrid van Geel, MD

Role: STUDY_CHAIR

AstraZeneca

Ingeborg Vosjan, MD

Role: STUDY_CHAIR

AstraZeneca

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TARGET

Identifier Type: -

Identifier Source: secondary_id

25V06

Identifier Type: -

Identifier Source: org_study_id